Literature DB >> 26253783

Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic.

Renzo Mancuso1, Xavier Navarro2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of upper and lower motoneurons, leading to muscle weakness and paralysis, and finally death. Considerable recent advances have been made in basic research and preclinical therapeutic attempts using experimental models, leading to increasing clinical and translational research in the context of this disease. In this review we aim to summarize the most relevant findings from a variety of aspects about ALS, including evaluation methods, animal models, pathophysiology, and clinical findings, with particular emphasis in understanding the role of every contributing mechanism to the disease for elucidating the causes underlying degeneration of motoneurons and the development of new therapeutic strategies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Motoneurons disease; Neurodegeneration; Neuromuscular junction; Neuroprotection

Mesh:

Year:  2015        PMID: 26253783     DOI: 10.1016/j.pneurobio.2015.07.004

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  35 in total

Review 1.  The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2018-07-08       Impact factor: 8.739

Review 2.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

3.  Imaging three-dimensional innervation zone distribution in muscles from M-wave recordings.

Authors:  Chuan Zhang; Yun Peng; Yang Liu; Sheng Li; Ping Zhou; William Zev Rymer; Yingchun Zhang
Journal:  J Neural Eng       Date:  2017-03-30       Impact factor: 5.379

4.  Specific Expression of Glial-Derived Neurotrophic Factor in Muscles as Gene Therapy Strategy for Amyotrophic Lateral Sclerosis.

Authors:  Guillem Mòdol-Caballero; Mireia Herrando-Grabulosa; Belén García-Lareu; Sergi Verdés; Rubén López-Vales; Gemma Pagès; Miguel Chillón; Xavier Navarro; Assumpció Bosch
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

Review 5.  Delivering Bad News in Amyotrophic Lateral Sclerosis: Proposal of Specific Technique ALS ALLOW.

Authors:  Wesleigh F Edwards; Sahana Malik; Jonathan Peters; Ivy Chippendale; John Ravits
Journal:  Neurol Clin Pract       Date:  2021-12

6.  EST79232 and EST79376, Two Novel Sigma-1 Receptor Ligands, Exert Neuroprotection on Models of Motoneuron Degeneration.

Authors:  Núria Gaja-Capdevila; Neus Hernández; Sandra Yeste; Raquel F Reinoso; Javier Burgueño; Ana Montero; Manuel Merlos; José M Vela; Mireia Herrando-Grabulosa; Xavier Navarro
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

Review 7.  SOD1 in ALS: Taking Stock in Pathogenic Mechanisms and the Role of Glial and Muscle Cells.

Authors:  Caterina Peggion; Valeria Scalcon; Maria Lina Massimino; Kelly Nies; Raffaele Lopreiato; Maria Pia Rigobello; Alessandro Bertoli
Journal:  Antioxidants (Basel)       Date:  2022-03-23

Review 8.  Could Sirtuin Activities Modify ALS Onset and Progression?

Authors:  Bor Luen Tang
Journal:  Cell Mol Neurobiol       Date:  2016-12-10       Impact factor: 5.046

Review 9.  Bile Acids: A Communication Channel in the Gut-Brain Axis.

Authors:  Vera F Monteiro-Cardoso; Maria Corlianò; Roshni R Singaraja
Journal:  Neuromolecular Med       Date:  2020-10-21       Impact factor: 3.843

10.  Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis.

Authors:  Guillem Mòdol-Caballero; Belén García-Lareu; Sergi Verdés; Lorena Ariza; Irene Sánchez-Brualla; Frédéric Brocard; Assumpció Bosch; Xavier Navarro; Mireia Herrando-Grabulosa
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.